Review on Drugs Acting on Candida Infection and Their Treatment

Due to the rise in immunocompromised patients, infections caused by Candida species have increased rapidly globally. Clinical practitioners have implemented a number of measures for the prevention and treatment of candidiasis. Fluconazole, amphotericin B, nystatin, and flucytosine are among the many antifungal medications that are frequently used to treat individuals with Candida infection. In addition, numerous efflux pump inhibitors have been developed and examined in various models for the successful treatment of candidiasis. Biomedicines, such as antibodies and polysaccharide-peptide conjugates, may be safer and more effective solutions for treating and preventing diseases than manufactured pharmaceuticals, which can have negative side effects. Additionally, the ability to investigate how genes function in adhesion, penetration, and other processes has been made possible by the availability of genome sequences of Candida albicans and other non-albicans strains. For a considerable amount of time, harmless commensals known as Candida species have been associated with humans. They are frequently observed on human skin, gastrointestinal, and genitourinary tract mucosal surfaces. However, in patients with impaired immune systems, they transform into opportunistic infections. Because they are opportunistic pathogens, they can lead to systemic infections as well as localized mucosal infections. The effective management of candidiasis has faced a significant and daunting challenge as a result, and costs have multiplied.